היזנטרה ישראל - עברית - Ministry of Health

היזנטרה

csl behring ltd., israel - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 200 mg / 1 ml - immunoglobulins, normal human, for extravascular adm.

פריוויג'ן ישראל - עברית - Ministry of Health

פריוויג'ן

csl behring ltd., israel - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 100 g/l - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - 1. replacement therapy in- primary immunodeficiency syndromes such as:- congenital agammaglobulinaemia and hypogammaglobulinaemia- common variable immunodeficiency- severe combined immunodeficiency- wiskott-aldrich syndrome- myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections-children with congenital aids and recurrent infections2. immunomodulation- immune thrombocytopenic purpura (itp) in children or adults at high risk of bleeding or prior to surgical interventions to correct the platelet count-guillain-barr? syndrome- kawasaki disease3. allogeneic bone marrow transplantation

רופילק 300 ישראל - עברית - Ministry of Health

רופילק 300

csl behring ltd., israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - prophylaxis of rh (d) immunisation in rh (d)-negative women: anti-d immune globulin is administered for the prevention of rh (d) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. treatment is not necessary when it is assured that the child or the father are rh (d)- negative. criteria for a rhesus-incompatible pregnancy and the administration of anti-d immune globulin are : a) the mother is rh (d) -negative b) the child is either rh (d)-positive rh (d)weak - positive or its rhesus type is not known. routine antepartum prophylaxis : to prevent rh (d) immunisation due to spontaneous fetomaternal haemorrhage (fmh) during the last trimester of pregnancy. postpartum prophylaxis to prevent rh (d) immunisation of the rh (d)-negative mother following delivery of a rh (d)-positive child. complications of pregnancy: interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

ברינרט ישראל - עברית - Ministry of Health

ברינרט

csl behring ltd., israel - c - 1 esterase inhibitor human - אבקה להמסה להזרקה\אינפוזיה - c - 1 esterase inhibitor human 500 iu/vial - c1- inhibitor,plasma derived - c1- inhibitor,plasma derived - hereditary angioedema type i and ii (hea) , treatment of acute episodes.

המוקומפלטן פי 1 ג' ישראל - עברית - Ministry of Health

המוקומפלטן פי 1 ג'

csl behring ltd., israel - human fibrinogen - אבקה להמסה להזרקה\אינפוזיה - human fibrinogen 900 - 1300 mg / 1 vials - fibrinogen, human - fibrinogen, human - haemocomplettan p 1g/2g, fibrinogen concentrate (human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.haemocomplettan p 1g/2g is not indicated for dysfibrinogenemia.

המוקומפלטן פי 2 ג' ישראל - עברית - Ministry of Health

המוקומפלטן פי 2 ג'

csl behring ltd., israel - human fibrinogen - אבקה להמסה להזרקה\אינפוזיה - human fibrinogen 1800 - 2600 mg / 1 vials - fibrinogen, human - fibrinogen, human - haemocomplettan p 1g/2g, fibrinogen concentrate (human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.haemocomplettan p 1g/2g is not indicated for dysfibrinogenemia.

בריפלקס PN 250 ישראל - עברית - Ministry of Health

בריפלקס pn 250

csl behring ltd., israel - coagulation factor ii (human); coagulation factor ix (human- rfixfc); coagulation factor vii (human); coagulation factor x (human); protein c; protein s antigen - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ii (human) 200 - 480 iu; coagulation factor vii (human) 100 - 250 iu; coagulation factor ix (human- rfixfc) 200 - 310 iu; coagulation factor x (human) 220 - 600 iu; protein c 150 - 450 iu; protein s antigen 120 - 380 iu - coagulation factor ix, ii, vii and x in combination - coagulation factor ix, ii, vii and x in combination - -treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

האמט פי 1000IU FVIII  2400IU VWF ישראל - עברית - Ministry of Health

האמט פי 1000iu fviii 2400iu vwf

csl behring ltd., israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - factor viii (human) 1000 iu / 15 ml; von willebrand factor 2400 iu / 15 ml - coagulation factor viii - coagulation factor viii - congenital and acquired deficiency of blood clotting factor viii: severe or moderate haemophilia,prophylaxis during operation, von willebrands disease.

האמט פי 250IU FVIII  600IU VWF ישראל - עברית - Ministry of Health

האמט פי 250iu fviii 600iu vwf

csl behring ltd., israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - factor viii (human) 250 iu / 5 ml; von willebrand factor 600 iu / 5 ml - coagulation factor viii - coagulation factor viii - congenital and acquired deficiency of blood clotting factor viii: severe or moderate haemophilia, prophylaxis during operation, von willebrand's disease.

פיברוגאמין 250IU FXIII ישראל - עברית - Ministry of Health

פיברוגאמין 250iu fxiii

csl behring ltd., israel - factor xiii - powder for solution for injection - factor xiii 200 - 320 iu - coagulation factor xiii - coagulation factor xiii - congenital or acquired factor xiii deficiency, or to promote healing of wounds and bone fractures. congenital deficiency of factor xiii and resultant haemorrhagic syndroms